Atossa Therapeutics ( ($ATOS) ) has shared an announcement. On December 4, 2025, Atossa Therapeutics announced the completion of a Type C meeting ...

Simulations Plus' silico software boosts non-animal drug development and drives growth. Read here for an investment analysis ...

Now, it’s worth noting Stock Advisor's total average return is 1,022% — a market-crushing outperformance compared to 188% for the S&P 500. Don’t miss out on the latest top 10 list, available when you ...

Special Report: Clinical stage biotech Tryptamine Therapeutics has secured firm commitments from new and existing ...

Research and development expenses were $27.1 million for the third quarter of 2025, compared to $16.8 million for the third quarter of 2024. The increase primarily reflects increases in clinical trial ...

ORMP READ THE FULL ORMP RESEARCH REPORT ADVANCING ORMD-0801 THROUGH CLINICAL STUDIES Trial will focus on key patient subpopulations that have responded to ORMD-0801 following analysis of earlier trial ...

Celcuity has successfully transitioned from a speculative biotechnology company to a pre-commercial firm with a de-risked ...

ARMR Sciences of New York is trialing a vaccine in the Netherlands to protect against fentanyl-related overdose and death.

MediWound Ltd. (NASDAQ: MDWD) Q3 2025 Earnings Call Transcript November 20, 2025 MediWound Ltd. beats earnings expectations.

Company advances JOTROL™ into Phase 2a Parkinson’s trial, launches Nugevia™ consumer brand, and strengthens financial positionJupiter, Florida, ...

Launched sales of Arbli™ (losartan potassium). Net revenue increased from approximately $65 thousand to $590 thousand. Gross profit increased from approximately $4 thousand to $575 thousand. "Q3 was a ...

The ASX healthcare sector ended the week ending November 21, 2025 down, following a sharp sell-off as on Wall Street and ...